KyungDong Pharm home
Prescription Medicines

Selecaduo Tab.

Product Category
Arthritis treatment
Active Ingredients
Celecoxib, angelica root and 11 other soft extracts
Appearance
Yellow, oblong, film-coated tablet consisting of two layers
Reimbursement Code
648104940
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
- Active ingredients:
25% ethanol soft extract (3.5→1) of Angelica, Chaenomeles, Saposhnikovia, Dipsacus, Acanthopanax, Achyranthes, Clematis, cinnamon, Gentiana, Cnidium, Gastrodia, and safflower (in-house specification) ·················· 405.4 mg
Celecoxib (in-house specification) ·················· 100 mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: light anhydrous silicic acid, glyceryl behenate, sodium lauryl sulfate, magnesium stearate, opadry yellow (80W42096), crospovidone, polyacrylic potassium, hydroxypropyl cellulose

2. Effectiveness
Relief of symptoms and signs of osteoarthritis (degenerative arthritis)

3. Dosage and dosage
Adults: Take 2 times a day, 1 tablet each time.
This medicine can be administered without regard to meals. Take this medicine whole without crushing or dividing it.

○ Patients with liver impairment
In the initial treatment of patients with hepatic impairment who require dosage reduction, administration of this drug is not recommended. (5. General precautions among precautions for use)

4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular thrombotic events: This drug may increase the risk of serious cardiovascular thrombotic events, myocardial infarction and stroke, which can be fatal. Similar risks may occur with all nonsteroidal anti-inflammatory drugs. This risk may increase depending on the administered dose and administration period. The relative increase from baseline in serious cardiovascular thrombotic events due to NSAID drugs was similar regardless of the presence or absence of cardiovascular disease or cardiovascular risk factors, but the absolute incidence rate was observed to be higher due to the increased rate of baseline cardiovascular thrombotic events. To minimize the potential risk of adverse cardiovascular events in patients treated with this drug, it should be used at the lowest effective dose and for the shortest possible period. Physicians and patients should carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance of the measures to be taken if signs and symptoms of serious cardiovascular toxicity (chest pain, shortness of breath, weakness, slurred speech) develop.
3) Gastrointestinal risk: Upper and lower gastrointestinal perforation, ulceration, or bleeding occurred in patients treated with this drug. Nonsteroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration. While administering this drug, patients should be carefully monitored for signs and symptoms of gastrointestinal ulcers or bleeding. If suggestive symptoms, including pain in the solar plexus, dyspepsia, melena, or hematemesis, or severe gastrointestinal adverse reactions are suspected, additional evaluation and treatment should be performed immediately. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.

2. Do not administer to the following patients
1) Patients with or history of hypersensitivity to this drug or its components
2) Patients with a history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria, or allergic reactions to COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs.
3) Patients with severe cardiovascular disease, patients with severe liver impairment, patients with severe renal impairment (patients with creatinine clearance < 30 mL/min)
4) Active peptic ulcer or gastrointestinal bleeding
5) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
6) Patients with congestive heart failure (NYHA II - IV)
7) Patients with established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
8) Pregnant women or women who may be pregnant (there is a risk of miscarriage or premature birth due to the herbal medicines such as aster and safflower contained in this medicine.)
9) Nursing mothers
10) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
11) Patients with hyperkalemia
12) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients:
1) Patients with hepatic impairment or a history of it
2) Patients with renal impairment or a history of it (patients with creatinine clearance <60 mL/min)
3) Patients with bronchial asthma
4) Patients with heart failure or a history of it
5) Patients with high blood pressure or a history of it
6) Patients with fluid retention or a history of edema
7) Patients taking diuretics or ACE inhibitors
8) Patients at risk of hypovolemia
9) Dehydrated patients
10) Elderly people
11) Patients with a history of peptic ulcer or gastrointestinal bleeding
12) Patients with high risk factors for adverse cardiovascular events (heart attack, stroke, etc.) (e.g. high blood pressure, hyperlipidemia, diabetes, smoking, etc.), patients with cardiovascular disease or a history thereof
13) Patients with difficult metabolism by CYP2C9
14) Patients with blood coagulation disorders or receiving anticoagulants
15) Women planning to become pregnant (taking celecoxib may impair female fertility.)
16) Diabetics
17) Patients taking psychiatric medications

4. Adverse reactions
A. Adverse reactions reported in clinical trials conducted with this drug
1) As a result of comparing the safety data of this drug and the main ingredients that make up this drug, there was no new safety information added.
A clinical trial in patients with knee osteoarthritis (n = 354) compared the safety and efficacy of this medicine (test group) with celecoxib tablets (control group). After a 2-week celecoxib run-in period, patients received the test or control treatment for 8 weeks. Adverse events occurred in 14.12% of the test group (25/177 patients; 33 events) and 11.30% of the control group (20/177 patients; 24 events), with no statistically significant difference. Adverse drug reactions occurred in 2.82% of the test group (5/177 patients; 8 events) and 0.56% of the control group (1/177 patients; 1 event), also without a statistically significant difference. Neither group reported serious adverse events or serious adverse drug reactions.

<Status of adverse reactions by organ system>
- Refer to manual -

*When the frequency of adverse drug reactions of this drug was written based on very common (≥ 10 %), common (≥ 1 %, < 10 %), uncommon (≥ 0.1 %, < 1 %), rare (≥ 0.01 %, < 0.1 %), and very rare (< 0.01 %), it was as follows.
- Refer to manual -

B. Adverse reactions in clinical trials and post-marketing surveillance of celecoxib
1) Clinical trials
(1) Table 1 below shows adverse reactions that were reported at a higher rate than the placebo group with an incidence of > 0.01% in the celecoxib group in 12 placebo- and/or active drug-controlled clinical trials in adults in which celecoxib was administered at doses ranging from 100 mg to 800 mg per day for up to 12 weeks. The incidence was calculated based on the latest pooled results of 89 randomized, controlled clinical trials corresponding to clinical exposure of 38,102 patients taking celecoxib.
Definition of frequency of occurrence: [very common (≥ 10 %), common (≥ 1 %, < 10 %), uncommon (≥ 0.1 %, < 1 %), rare (≥ 0.01 %, < 0.1 %), very rare (< 0.01 %)]
The adverse reactions in Table 1 were classified by organ system and listed by frequency of occurrence.
[Table 1]. Adverse reactions in 12 placebo- and/or active drug-controlled clinical trials in adults and incidence estimates based on 89 randomized controlled clinical trials of pain and inflammation with celecoxib administered at doses ranging from 25 mg to 800 mg per day
- Refer to manual -

(2) According to a comparative clinical trial with placebo or active control drug, the discontinuation rate of drug administration due to adverse reactions was 7.1% in the celecoxib administration group and 6.1% in the placebo group. Among the adverse reactions that led to discontinuation of celecoxib administration, the most frequent were indigestion and abdominal pain. Regardless of the causal relationship with celecoxib, adverse reactions reported in adults after administration of celecoxib are as follows.
• Gastrointestinal system: indigestion (8.8%), diarrhea (5.6%), irritable bowel syndrome, increased frequency of bowel movements, occasional abdominal pain, epigastric pain, flatulence, nausea, constipation, diverticulitis, dysphagia, eructation, esophagitis, gastroenteritis, gastrointestinal ulcer, gastroesophageal reflux, gastric discomfort, gastrointestinal disorders, hemorrhoids, hiatal hernia, bloody stool, dry mouth, stomatitis, reflux, Dental disease, vomiting, worsening of gastrointestinal inflammation, angle of mouth erosion, rare cases of ileus, intestinal perforation, gastrointestinal bleeding, hemorrhagic colitis, esophageal perforation, pancreatitis, intestinal obstruction, post-tooth extraction alveolar osteitis, intestinal anastomosis ulcer, melena, glossitis, aphthous stomatitis, blistering of oral mucosa, numbness of the mouth, and pain in the oral cavity may occur.
• Central and peripheral nervous system: headache (15.8%), occasional dizziness, leg cramps, hypertonia, hypoesthesia, migraine, neuralgia, neuropathy, paresthesia, cerebral infarction, rarely aseptic meningitis, ataxia, suicide, anosmia, anosmia.
• Systemic: Occasionally back pain, exacerbation of allergies, allergic reaction, asthenia, chest pain, fluid retention/peripheral edema, generalized edema, facial edema, fatigue, malaise, fever, facial flushing, influenza-like syndrome, pain, peripheral pain, rarely sepsis, sudden death, anaphylactoid reaction, angioedema.
• Nervous system: Occasionally insomnia, anorexia, anxiety, increased appetite, depression, irritability, drowsiness, fatal intracranial hemorrhage, confusion, hallucinations, exacerbation of epilepsy.
• Respiratory system: upper respiratory tract infection (8.1%), sinusitis (5.0%), occasionally pharyngitis, rhinitis, bronchitis, bronchospasm, worsening bronchospasm, cough, dyspnea, laryngitis, pneumonia, rarely epistaxis, dysphonia.
• Skin and appendages: Bullous dermatitis, ecchymosis, occasional rash, alopecia, dermatitis, nail disease, photosensitivity reaction, pruritus, erythematous rash, maculopapular rash, skin disease, dry skin, increased sweating, urticaria, erythema multiforme, exfoliative dermatitis, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), eczema, lipoma, allergy. Dermatitis, rarely petechial hemorrhages, dandruff, drug rash with eosinophilia and systemic symptoms (DRESS or hypersensitivity reaction syndrome)
• Cardiovascular system: Arrhythmia, ventricular hypertrophy, sometimes exacerbated hypertension, hypertension, angina pectoris, unstable angina, coronary artery disease, myocardial infarction, heart failure, congestive heart failure, palpitations, tachycardia, stroke, aortic regurgitation, hematoma, sinus bradycardia, rarely syncope, ventricular fibrillation, pulmonary embolism, cerebrovascular attack, peripheral gangrene, thrombophlebitis, vasculitis, deep vein thrombosis, cerebral hemorrhage.
• Infections: Upper respiratory tract infections, erysipelas, wound infections, gingivitis, occasionally herpes simplex, herpes zoster, bacterial infections, fungal infections, soft tissue infections, viral infections, moniliasis, genital moniliasis, otitis media.
• Reproductive system: breast tenderness, menopausal symptoms, sometimes thoracic mammary fibromatosis, thoracic neoplasm (females), chest pain (females), dysmenorrhea, menstrual disorders, vaginal bleeding, vaginitis, prostate disorders, ovarian cysts.
• Ears: Sometimes hearing loss, ear abnormalities, ear pain, tinnitus, hearing loss.
• Liver and biliary system: Occasionally abnormal liver function, increased ALT, increased AST, increased γ-GTP, increased ALP, positive urinary urobilinogen, rarely cholelithiasis, hepatitis, jaundice, liver failure, fulminant hepatitis, liver necrosis.
• Metabolism and nutrition: increased blood sodium, increased blood potassium, sometimes increased BUN, increased CPK, diabetes mellitus, hypercholesterolemia, hyperglycemia, hypokalemia, hyperkalemia, increased NPN, increased creatinine, increased alkaline phosphatase, weight gain, loss of appetite, increased LDH, rarely hypoglycemia, hyponatremia.
• Skeletal muscular system: synovial cyst, sometimes arthralgia, arthrosis, skeletal abnormalities, muscle pain, cervical tension, synovitis, tendinitis, myositis, leg cramps, fractures, tendon rupture, rarely back pain, muscle stiffness.
• Blood system: decreased hematocrit, increased hemoglobin, sometimes ecchymosis, epistaxis, thrombocytosis, anemia, rarely thrombocytopenia, agranulocytosis, aplastic anemia, pancytopenia, leukopenia.
• Administration site: Occasionally cellulitis, contact dermatitis, injection site reaction, skin nodules
• Special organs: sometimes taste buds.
• Urinary tract: Occasionally albuminuria, cystitis, hematuria, dysuria, urinary frequency, nephrolithiasis, urinary incontinence, urinary tract infection.
• Eyes: Sometimes blurred vision, cataracts, conjunctivitis, eye pain, glaucoma, rarely intraocular hemorrhage, retinal artery or vein occlusion.
• Kidney: Increased blood creatinine, increased β2-microglobulin, occasionally increased NAG, positive urinary occult blood, positive urine protein, rarely renal dysfunction, acute renal failure, interstitial nephritis.

2) Domestic post-marketing survey results
(1) As a result of a post-marketing use results survey conducted in Korea for 6 years, 338 adverse reactions were reported in 305 cases (5.40%) out of a total of 5,648 cases, regardless of causal relationship with celecoxib. Indigestion was the most common with 155 cases (2.74%), facial edema 54 cases (0.96%), abdominal pain 33 cases (0.58%), nausea 13 cases (0.23%), peripheral edema and rash 12 cases each (0.21%), diarrhea 10 cases (0.18%), and insomnia 7 cases (0.12%). Appeared in order.
(2) As other adverse reactions, headache and dizziness were reported in 5 cases each (0.09%), constipation, stomach ulcers, urticaria, and anemia were reported in 2 cases each (0.04%), and dry mouth, ulcerative stomatitis, gastritis, allergy, back pain, chest pain, hyperlipidemia, diabetes, weight gain, fracture, joint pain, RA factor positivity, shingles, pneumonia, difficulty breathing, elevation of ALT, and hearing loss were reported. 1 case (0.02%) was reported.

3) Overseas post-marketing survey results
Adverse reactions identified in post-marketing experience are as follows. Although these adverse reactions were confirmed in post-marketing reports, clinical trial data were referenced to assess frequency. As above, the incidence is based on the combined results of clinical trials representing exposure in 38,102 patients.
Definition of frequency: [Very common (≥ 10 %), common (≥ 1 %, < 10 %), uncommon (≥ 0.1 %, < 1 %), rare (≥ 0.01 %, < 0.1 %), very rare (< 0.01 %), frequency unknown (cannot be evaluated with existing data)
(1) Immune system: Very rare anaphylactic reaction
(2) Mental system: Rarely hallucinations
(3) Nervous system: Very rarely, cerebral hemorrhage, aseptic meningitis, loss of taste, loss of smell.
(4) Eyes: uncommon conjunctivitis
(5) Blood vessels: Very rarely vasculitis
(6) Respiration, chest and mediastinum: rarely, pulmonary embolism, interstitial pneumonia
(7) Gastrointestinal tract: rare gastrointestinal bleeding
(8) Hepatobiliary tract: rarely hepatitis, very rarely liver failure, fulminant hepatitis, liver necrosis, cholestasis, cholestatic hepatitis, jaundice
(9) Skin and subcutaneous tissue: Rare photosensitivity reaction, very rare Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug rash with increased eosinophils and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), exfoliative dermatitis.
(10) Kidney and urinary system: rarely acute renal failure, hyponatremia, very rarely tubulointerstitial nephritis, nephrotic syndrome, microlesional glomerulonephritis.
(11) Reproductive system and breast: Rare menstrual disorder, frequency unknown† - Female infertility (reduced female fertility)
(12) Whole body and administration site: Uncommon chest pain
†Women planning pregnancy were excluded from all clinical trials, so it is not appropriate to refer to clinical trial data for the frequency of this adverse reaction.

c. Adverse reactions in clinical trials and post-marketing surveillance of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, Safflower 25% Ethanol Soft Extract (3.5 → 1)’ tablets
1) Clinical trials
As a result of a domestic phase 3 clinical trial administered to patients with knee osteoarthritis for 8 weeks, the following adverse reactions that occurred in 154 patients who received the test drug that were ‘possibly related’ or higher to the test drug were as follows, and there were no serious adverse reactions. [Rarely (less than 0.1%), Occasionally (less than 0.1 to 5%)]
(1) Digestive system: Heartburn or indigestion (6.5%), sometimes dry mouth (0.65%), nausea (0.65%), diarrhea (0.65%)
(2) Whole body: Occasionally facial edema (4.55%), whole body edema (0.65%), weakness (0.65%)
(3) Metabolic system: Occasionally hypertriglyceridemia (1.3%), hypercholesterolemia (0.65%), transaminitis (0.65%), increased ALT (0.65%), increased AST (0.65%)
(4) Skin: Occasionally itchy (1.3%)
(5) Blood: Occasionally decreased white blood cells (total WBC) (0.65%), decreased neutrophils (0.65%)
(6) Others: Occasional chest discomfort (0.65%), headache (0.65%), upper respiratory tract infection (0.65%), blurred vision (0.65%)
2) Domestic post-marketing survey results
(1) As a result of a post-marketing survey conducted on 1,133 people over 4 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 9.44% (107/1133 people, 129 cases in total) regardless of causal relationship. Among these, the occurrence rate of serious adverse events was 0.88% (10/1133 people, 12 cases in total), gastric bleeding 0.18% (2/1133 people, 2 cases), colon polyp, reflux esophagitis, fracture, leg fracture, polymyalgia rheumatica, liver abscess, intracranial hemorrhage, mitral valve dysfunction, pyelonephritis, and pneumonia each at 0.09%. % (1/1133 people, 1 case) reported. No serious adverse events were reported where a causal relationship with the tablets of ‘Angelica, Quince, Windbreak, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’ could not be ruled out. The occurrence rate of unexpected adverse events was reported to be 5.56% (63/1133 people, 75 cases in total) regardless of causal relationship, 0.79% for colds (9/1133 people, 10 cases), 0.44% for solar plexus discomfort (5/1133 people, 5 cases), and 0.26% each for gastritis and urticaria (3/1133 people, 5 cases). 3 cases), fractures 0.18% (2/1133 people, 3 cases), constipation, epigastric pain, gastric bleeding, enteritis, pneumonia, toe fracture, thyroid nodule each 0.18% (2/1133 people, 2 cases), colonic polyps, white tongue, duodenal ulcer, reflux esophagitis, gastroesophageal reflux, gastric polyposis, atrophic gastritis, intestinal obstruction, Phlegm abnormalities, bronchitis, rib fractures, tenosynovitis, leg fractures, polymyalgia rheumatica, neck/shoulder pain, non-inflammatory joint swelling, cystitis, dysuria, renal cyst, pyelonephritis, chest pain, flu-like symptoms, back pain, rosacea, alopecia, fatty liver, liver abscess, benign prostatic hyperplasia, kidney cancer, intracranial hemorrhage, mitral valve dysfunction, Burns, paresthesia, depression, tinnitus, bitterness, and bruises were found to be 0.09% (1/1133 people, 1 case). Among these, the occurrence rate of unexpected adverse events for which a causal relationship cannot be ruled out with the tablets of ‘Angelica, Quince, Windbreak, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, Safflower 25% Ethanol Soft Extract (3.5 → 1)’ was 0.79% (9/1133 people, 9 cases in total), including gastritis 0.26%. % (3/1133 people, 3 cases), epigastric pain at 0.18% (2/1133 people, 2 cases), and solar plexus discomfort, constipation, gastroesophageal reflux, and urticaria at 0.09% each (1/1133 people, 1 case).
(2) Among other voluntarily reported adverse events, 2 cases of hives, gastritis, gastric pain, reflux esophagitis, gastritis, gastric pain, reflux esophagitis, gastritis, gastric pain, reflux esophagitis, discomfort in the solar plexus, and unrelated to food were reported as unexpected adverse events in which a causal relationship with the tablets of ‘Angelica, Quince, Windbreak, Sokdan, Acanthopanax, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’ tablets cannot be ruled out. One case each of solar plexus pain and insomnia was reported.
(3) Domestic re-examination adverse event and spontaneous side effect report data for ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, Safflower 25% Ethanol Soft Extract (3.5 → 1)’ tablets were integrated with adverse event report data reported for all drugs approved for domestic market (1989 - August 2016) at the end of reexamination. As a result of the evaluation, the newly identified adverse events that were statistically significantly more reported in the tablet compared to the adverse events reported in all other medicines are as follows. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
● Nervous system: dizziness, drowsiness
● Digestive system: gastritis, gastroesophageal reflux
● Abnormalities in the entire body and administration site: peripheral edema

5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. As the dose and exposure period of celecoxib increase, the cardiovascular risk increases, so administer it at the lowest effective dose for the shortest possible period. In particular, patients with osteoarthritis (degenerative arthritis) should be re-evaluated periodically.
2) Gastrointestinal effects: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including celecoxib, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, concurrent use of nonsteroidal anti-inflammatory drugs or aspirin, alcohol consumption, cardiovascular disease, smoking, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering celecoxib to these patients.
As a result of clinical trials administering tablets of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’, heartburn (or indigestion) that may be related to the test drug was observed in some patients, so special caution is required when administering to patients with a history of peptic ulcer.
3) Hypertension: Non-steroidal anti-inflammatory drugs, including celecoxib, may cause hypertension or worsen existing hypertension, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Nonsteroidal anti-inflammatory drugs, including celecoxib, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of celecoxib.
4) Congestive heart failure and edema: Fluid retention and edema were observed in some patients taking non-steroidal anti-inflammatory drugs, including celecoxib. Because inhibition of prostaglandin synthesis may cause deterioration of renal function and fluid retention, celecoxib should be administered with caution in patients with a history of heart failure, left ventricular dysfunction, or hypertension, or in patients with edema or fluid retention. Additionally, caution should be exercised when administering celecoxib to patients taking diuretics or at risk of hypovolemia for other reasons.
As a result of clinical trials administering tablets of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’, edema (or facial edema) that may be related to the test drug was observed in some patients, so special caution is required when administering to patients with fluid retention or heart failure.
5) Effect on kidneys: Non-steroidal anti-inflammatory drugs, including celecoxib, can cause nephrotoxicity. The effects of celecoxib on the kidneys seen in celecoxib clinical trials were similar to those observed in the nonsteroidal anti-inflammatory drugs used as reference drugs. Long-term use of non-steroidal anti-inflammatory drugs may cause renal papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients at greatest risk of nephrotoxicity, such as patients with renal dysfunction, heart failure, liver dysfunction, patients taking diuretics, ACE inhibitors, or angiotensin II antagonists, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of celecoxib in patients with advanced renal disease. Therefore, administration of celecoxib is not recommended for patients with advanced renal disease. If treatment with celecoxib must be initiated, the patient's renal function should be closely monitored.
7) Effects on the liver: Not studied in patients with severe hepatic impairment (Child-Pugh Class C). Administration of non-steroidal anti-inflammatory drugs, including celecoxib, may result in an increase in liver function levels. These abnormal test values ​​may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal or required liver transplantation) were rarely reported with the administration of non-steroidal anti-inflammatory drugs, including this drug. For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration of celecoxib should be discontinued.
8) If symptoms or signs of anemia or blood loss appear due to long-term administration of celecoxib, a hemoglobin level or hematocrit test should be performed. Celecoxib generally does not affect platelet counts, prothrombin time (PT), or partial thromboplastin time (PTT), and does not inhibit platelet aggregation at recommended doses.
9) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, administration of celecoxib should be discontinued.
While administering ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, Safflower 25% Ethanol Soft Extract (3.5 → 1)’, pay attention to the occurrence of adverse reactions in the cardiovascular system, gastrointestinal system, liver function, or renal function. If an adverse reaction occurs, appropriate treatment such as immediate withdrawal or discontinuation of administration and detailed diagnosis should be performed.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If this type of anaphylactic reaction occurs, emergency treatment should be administered.
As a result of clinical trials administering tablets of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’, no cases of anaphylactic reactions were reported.
11) Skin reactions: Celecoxib is a sulfonamide class drug that can cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms and may occur even in patients without a history of sulfa drug allergy. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin manifestations and symptoms and should stop taking the drug at the first signs and symptoms of hypersensitivity reactions such as skin rash, mucosal lesions or blisters, fever, and itching.
A rash, etc. may appear during use due to the herbal medicine Cheonma contained in ‘Angelica, quince, windbreak, sokdan, acacia, eucalyptus, weiryeongseon, broiler, jingyo, Cheongung, Cheonma, safflower 25% ethanol soft extract (3.5 → 1)’, so in such cases, you should immediately stop taking it and consult a specialist.
12) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, celecoxib should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
13) Celecoxib cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. When administering celecoxib to a patient who has been taking corticosteroids for a long period of time, the dose should be reduced gradually.
‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, Safflower 25% Ethanol Soft Extract (3.5 → 1)’ cannot be used as a substitute for corticoid preparations or as a drug to treat corticoid deficiency.
14) Due to the pharmacological properties of the main ingredients that make up this drug, fever and other symptoms and signs of inflammation may be suppressed, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
15) For patients showing symptoms of severe dehydration, administer medication after providing fluids and observe carefully.
16) The incidence of myocardial infarction and stroke increased as a result of two large-scale controlled clinical trials in which COX-2-selective NSAIDs were administered to treat pain in the first 10 to 14 days immediately after coronary artery bypass grafting (CABG).
17) Clinical tests (urinalysis, blood test, kidney function test, liver function test, electrocardiogram, fecal occult blood test, etc.) should be conducted on a regular or as needed basis, and if abnormalities are found, appropriate measures such as withdrawal of medication or discontinuation of administration should be taken.
18) Patients who experience dizziness or drowsiness after taking this drug should avoid driving or operating machinery.
19) Celecoxib has no effect on platelet function, so it cannot be an alternative to acetylsalicylic acid for the prevention of cardiovascular thromboembolic disease. Because celecoxib does not inhibit platelet aggregation, patients receiving antiplatelet therapy (e.g., acetylsalicylic acid) should not discontinue treatment.
20) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
21) Cross-sensitivity: Patients who are sensitive to one NSAID may also be sensitive to other NSAIDs.
22) Patients with autoimmune diseases (e.g., patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)) may have an increased risk of developing aseptic meningitis when taking celecoxib.
23) Hyperkalemia may occur when celecoxib is administered to diabetic patients or in combination with drugs that increase blood potassium levels, so regular monitoring of potassium levels is necessary in these cases.
24) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
25) Because of the herbal medicines Cheongung and Dong Quai contained in this drug, loss of appetite, stomach discomfort, nausea, vomiting, diarrhea, etc. may occur in patients with a significantly weak stomach. Therefore, be sure to consult a doctor or pharmacist before using this drug. If these symptoms appear while taking this drug, you must immediately stop taking it and consult a doctor or pharmacist.

6. Interaction
No studies have been conducted on drug interactions with specific drugs for this drug.
The interactions of the individual active ingredients contained in this medicine are as follows.
A. Celecoxib
1) Celecoxib is mainly metabolized by CYP2C9 in the liver, so caution should be exercised when coadministering this drug with drugs that inhibit CYP2C9. Caution should be exercised when administering celecoxib in patients suspected to be poor metabolizers of CYP2C9 based on previous history or experience with other CYP2C9 substrates, as plasma concentrations may increase abnormally due to decreased clearance. Consider starting treatment at half the lowest recommended dose.
When celecoxib and CYP2C9 inhibitors are coadministered, the plasma concentration of celecoxib may increase. Therefore, when celecoxib is coadministered with a CYP2C9 inhibitor, a dose reduction of celecoxib may be necessary.
Plasma concentrations of celecoxib may be decreased when celecoxib is coadministered with CYP2C9 inducers such as rifampicin, carbamazepine, and barbiturates. Therefore, when celecoxib is coadministered with a CYP2C9 inducer, an increase in the dose of celecoxib may be necessary.
2) Fluconazole and ketoconazole: When fluconazole 200 mg is administered together once a day, the metabolism of celecoxib through CYP2C9 is inhibited by fluconazole, and the blood concentration of celecoxib increases two-fold. Therefore, when starting concurrent use of celecoxib, administer at half the recommended dose.
Ketoconazole, a CYP3A4 inhibitor, did not show clinically significant inhibition of the metabolism of celecoxib.
3) CYP2D6: According to pharmacokinetic clinical studies and in vitro studies, celecoxib is not a substrate of CYP2D6 but has been found to be an inhibitor, so it may interact in vivo with drugs metabolized by CYP2D6. When coadministered with celecoxib, blood levels of CYP2D6 substrates such as antidepressants (tricyclics and SSRIs), neuroleptics, antiarrhythmic drugs, and dextromethorphan may increase. When starting concomitant administration of celecoxib, a dose reduction of these drugs may be necessary, and when concomitant administration of celecoxib is discontinued, the dosage of these drugs may need to be increased.
4) In an in vitro study, it was confirmed that celecoxib partially inhibits metabolism mediated by CYP2C19. The clinical significance of these results is unknown, but drugs metabolized by CYP2C19 include diazepam, citalopram, and imipramine.
5) Antihypertensive drugs, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (angiotensin receptor blockers, ARBs), diuretics, and beta-blockers: Inhibition of prostaglandins may reduce the effectiveness of antihypertensive drugs, including ACEIs, ARBs, diuretics, and beta-blockers, so celecoxib and ACEIs, ARBs, diuretics, and beta-blockers are recommended. Caution should be exercised regarding this interaction during co-administration. When NSAIDs, including selective COX-2 inhibitors (celecoxib), are coadministered with ACE inhibitors, angiotensin II receptor antagonists, or diuretics to volume-depleted patients, including those with reduced renal function, the elderly, or those taking diuretics, it may lead to decreased renal function, including acute renal failure. Therefore, caution should be exercised when administering this combination, especially to the elderly. Patients should be adequately hydrated, and renal function should be monitored regularly after starting this combination treatment.
Lisinopril Study Results: In a 28-day controlled clinical trial of lisinopril in patients with hypertension stage I and II, co-administration of celecoxib 200 mg twice daily (BID) did not result in a clinically significant increase in mean daily systolic or diastolic blood pressure as measured by 24-hour ambulatory blood pressure monitoring compared with placebo co-administration. Among patients receiving celecoxib 200 mg BID in combination, 48% had no response to lisinopril (defined as diastolic blood pressure > 90 mmHg or > 10% increase in diastolic blood pressure compared to baseline) at the final clinical visit, compared to 27% of patients receiving placebo, a statistically significant difference.
6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to celecoxib's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
7) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. It can be administered in combination with low-dose aspirin (less than 325 mg per day), but it has been reported that the incidence of gastrointestinal adverse reactions (gastrointestinal ulcers) or other gastrointestinal complications is higher than when celecoxib is administered alone. When aspirin is administered as preventive therapy for the cardiovascular system, celecoxib does not have an effect on platelets and therefore cannot be a substitute for aspirin.
8) Dextromethorphan and metoprolol: When celecoxib 200 mg was co-administered twice a day, the plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates) increased by 2.6-fold and 1.5-fold, respectively. This increase is because celecoxib inhibits CYP2D6 substrate metabolism through CYP2D6. Therefore, when starting celecoxib, the dosage of drugs that are CYP2D6 substrates may need to be reduced, or when celecoxib is stopped, the dosage of drugs that are CYP2D6 substrates may need to be increased.
9) Lithium: When celecoxib and lithium are administered together in healthy adults, the serum lithium concentration increases by about 17% and the renal clearance rate of lithium may decrease due to inhibition of prostaglandin synthesis in the kidney. Therefore, patients receiving lithium should be carefully observed for signs of lithium toxicity when starting or stopping celecoxib treatment.
10) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered together with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate. There was no significant effect when celecoxib was administered in combination with methotrexate (rheumatoid treatment dose) in patients with rheumatoid arthritis. However, if the two drugs are coadministered, appropriate monitoring for methotrexate-related toxicity should be considered.
11) Oral anticoagulants: When NSAIDs and oral anticoagulants are administered together, the risk of bleeding may increase, so they should be administered with caution. Oral anticoagulants include warfarin/coumarins and newer anticoagulants (e.g., apixaban, dabigatran, rivaroxaban). Warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
According to a test in which 2 to 5 mg of warfarin per day was administered to healthy subjects to determine the effect of celecoxib on the anticoagulant activity of warfarin, there was no effect on the anticoagulant activity as measured by prothrombin time. However, according to post-marketing surveillance, serious bleeding associated with prolongation of the prothrombin time, which may be fatal, has been reported in patients receiving warfarin and celecoxib concomitantly, especially in the elderly.
Prolongation of prothrombin time (INR) has been reported, so anticoagulation/INR should be monitored after starting or changing the dose of celecoxib in patients taking warfarin/coumarin anticoagulants.
12) Cyclosporine: Since the nephrotoxicity of cyclosporine or tacrolimus may increase due to co-administration of non-steroidal anti-inflammatory drugs and cyclosporine or tacrolimus, renal function should be monitored when co-administered with these drugs.
13) When celecoxib was taken with a high-fat diet, the peak plasma concentration was delayed by about 1 to 2 hours, and the total absorption (AUC) increased by 10 to 20%.
14) When celecoxib was administered in combination with antacids containing aluminum or magnesium, there was a 37% decrease in peak blood concentration and a 10% decrease in total absorption.
15) In addition to low-dose aspirin (less than 325 mg per day), co-administration with other non-steroidal anti-inflammatory drugs should not be done as the risk of adverse reactions may increase.
16) Corticosteroids: There is a risk of increased adverse reactions in the gastrointestinal system (e.g. ulcers, bleeding). There is a particular risk for elderly people (over 65 years of age).
17) Oral contraceptives: In an interaction study, celecoxib did not have a clinically significant effect on the pharmacokinetics of a combined oral contraceptive (norethindrone 1 mg/ethinyl estradiol 0.035 mg).
18) When used in combination with fluvastatin, the blood concentration of celecoxib and fluvastatin may increase.
19) Other drugs: No clinically significant interactions were observed when omeprazole, glibenclamide (glyburide), phenytoin, tolbutamide, and celecoxib were administered together.
B. No research has been conducted on drug interactions with specific drugs for ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’.

7. Administration to pregnant and lactating women
1) There is no clinical data on the administration of this drug or each of its main ingredients to pregnant women.
2) In experiments on rats, it has been reported that celecoxib does not delay parturition. However, the effect of celecoxib on labor and delivery in pregnant women is not known.
3) In a rabbit embryo/fetal development test, when celecoxib was administered orally at a dose of 150 mg/kg/day or more (about twice the AUC0-24 when administered to humans at 200 mg twice a day), the incidence of fetal abnormalities such as rib fusion and sternal segment fusion and the incidence of ventricular septal defects rarely increased. In a rat embryo/fetal development study, a dose-dependent increase in diaphragmatic hernia was observed in fetuses when celecoxib was administered orally at a dose of 30 mg/kg/day or more (equivalent to approximately 6 times the AUC0-24 when administered to humans at 200 mg twice a day) in one of the two tests. In addition, when celecoxib was administered to rats at a dose of 50 mg/kg/day or more (a dose equivalent to about 6 times the AUC0-24 when administered to humans at 200 mg twice a day), it caused pre-implantation loss, post-implantation loss, and decreased fetal survival rate. Such toxicity was not observed during pregnancy 2 weeks after discontinuation of drug administration.
4) In animal experiments (rabbits and rats), administration of celecoxib resulted in reproductive toxicity, including teratogenicity, but the potential risk in human pregnancy is unknown. In addition, like other drugs that inhibit prostaglandin synthesis, celecoxib can cause uterine atony or premature closure of the fetal ductus arteriosus when administered late in pregnancy, so celecoxib should not be administered to pregnant women or women who may become pregnant. If pregnancy is confirmed while administering celecoxib, administration of celecoxib is discontinued. Celecoxib is used in pregnancy only when the potential benefit to the mother justifies the potential risk to the fetus.
5) The use of non-steroidal anti-inflammatory drugs, including celecoxib, may interfere with or delay follicular rupture due to their mechanism of action, which may cause reversible infertility in some women. Therefore, women who have difficulty conceiving or are undergoing infertility tests should consider discontinuing the use of non-steroidal anti-inflammatory drugs, including celecoxib.
6) Inhibition of prostaglandin synthesis may have an adverse effect on pregnancy. Epidemiological studies have shown that the risk of spontaneous miscarriage increases after taking drugs that inhibit prostaglandin synthesis in early pregnancy. Animal tests showed that implantation failure increased when drugs that inhibit prostaglandin synthesis were administered.
7) Administration of non-steroidal anti-inflammatory drugs during the second or third trimester of pregnancy may cause abnormalities in fetal kidney function, which may lead to a decrease in the amount of amniotic fluid or oligohydramnios in severe cases. These effects may appear immediately after starting drug administration and are generally reversible. Amniotic fluid volume should be closely monitored in pregnant women taking celecoxib.
8) Celecoxib is excreted in rat breast milk at a concentration similar to that in plasma. Based on limited data from one subject, it is believed that it is also passed into human breast milk.
There is no clinical data on the administration of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’ to nursing mothers.
Many drugs not only pass into breast milk, but if they do so, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding should be discontinued or drug administration should be discontinued.

8. Administration to children
Safety and effectiveness in children and adolescents under 18 years of age have not been established.

9. Administration to elderly people
1) Elderly people are more likely to have decreased renal function, liver function, and especially cardiac function, so appropriate observation is required when administering this drug to the elderly.
2) According to clinical trials of celecoxib, there was no significant difference in effectiveness between elderly and young subjects. In clinical trials comparing kidney function (GFR, BUN, creatinine) and platelet function (bleeding time, degree of platelet aggregation), there were no differences between elderly and young subjects. However, as with other NSAIDs, including selective COX-2 inhibitors, post-marketing spontaneous adverse reactions of celecoxib for fatal gastrointestinal adverse reactions and acute renal failure were more frequently reported in elderly patients.
3) In general, dosage adjustment is not required for the elderly, but if the body weight is less than 50 kg, administration should be started at the lowest dose.

10. Effect on clinical test values
1) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should regularly undergo complete blood count (CBC) and physicochemical tests. If abnormal liver function test results or renal function test results persist or worsen, treatment with this drug should be discontinued.
2) Like other non-steroidal anti-inflammatory drugs, in clinical trials of celecoxib, BUN elevations were observed more frequently than placebo, but clinical significance was not confirmed.

11. Treatment in case of overdose
1) There have been no reports of overdose in clinical trials of this drug or its main ingredients.
2) No severe toxicity occurred when celecoxib was administered to 12 patients at a dose of up to 2,400 mg/day for up to 10 days.
3) Symptoms of overdosage of non-steroidal anti-inflammatory drugs generally include lethargy, drowsiness, nausea, vomiting, and upper abdominal pain, and can be recovered with auxiliary treatment. Gastrointestinal bleeding may also occur, and in rare cases, hypertension, acute renal failure, respiratory depression, and coma may occur.
4) Symptomatic and supportive treatment is usually performed, and there is no specific antidote.
5) If symptoms appear within 4 hours of taking celecoxib or if a very large dose is taken, vomiting, medicinal charcoal (60-100 g per kg for adults, 1-2 g per kg for children), or osmotic diarrhea can be used.
6) Treatments such as hemodialysis, forced diuresis, urinary alkalinization, and blood perfusion are not useful due to the high protein binding rate of celecoxib.

12. Precautions for storage and handling
1) It must be stored out of reach of children.
2) Caution must be taken as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

13. Information for experts
1) Pharmacokinetic information
(1) Drug interaction evaluation
2×2 between a group administered 100 mg of celecoxib tablets alone and a group administered together with 100 mg of celecoxib tablets and 405.4 mg tablets of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Extract (3.5 → 1)’ in 43 healthy adults. In a crossover test, pharmacokinetic interactions were evaluated by repeated administration twice a day on an empty stomach for 6 days (total of 11 times). When celecoxib was administered in combination compared to single administration, the 90% confidence interval of the log-transformed geometric mean ratio and mean difference of AUCτ and Cmax,ss was 1.0259 [0.9779 ~ 1.0762] and 1.0876 [1.0246 ~ 1.1545], all within 0.8 to 1.25. Therefore, it was confirmed that there was no pharmacokinetic interaction of ‘Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% Ethanol Soft Extract (3.5 → 1)’ with celecoxib.
(2) Bioavailability evaluation
A single-dose 2 × 2 crossover study in 44 healthy adults compared the pharmacokinetic equivalence of this product with coadministration of celecoxib 100 mg and a 405.4 mg tablet of a 25% ethanol soft extract (3.5→1) of Angelica, Chaenomeles, Saposhnikovia, Dipsacus, Acanthopanax, Achyranthes, Clematis, cinnamon, Gentiana, Cnidium, Gastrodia, and safflower. For celecoxib AUCt, the geometric mean ratio and 90% confidence interval were 1.1124 [1.0601–1.1672], within the equivalence range. For Cmax, the geometric mean ratio and 90% confidence interval were 1.2788 [1.1708–1.3969], outside the equivalence range (log 0.8 to log 1.25). Bioequivalence between this product and coadministration of the individual active ingredients was therefore not established. Patients taking celecoxib 100 mg together with 405.4 mg of the specified 25% ethanol soft herbal extract (3.5→1) must not be switched to this product alone.
2) Clinical trial information
A multicenter, randomized, double-blind, active-group controlled, parallel, phase 3 clinical trial was conducted on 356 patients with knee osteoarthritis (177 in the test group and 179 in the control group). In the introduction period, placebo and 100 mg of celecoxib tablets, 1 tablet each, twice a day for about 2 weeks without regard to meals were administered. After that, subjects with a 100 mm pain VAS of 40 mm or more and individual medication compliance of 70% or more were randomly assigned (baseline) to receive this drug or the active comparator, 100 mg of celecoxib tablets, 1 tablet each twice a day with meals for 8 weeks. Regardless, the efficacy and safety during administration were evaluated. The primary efficacy endpoint, the change in 100 mm pain VAS during activity at 8 weeks compared to the baseline, was -26.31 ± 1.35 mm in the test group and -14.59 ± 1.35 mm in the control group, and the difference in change between groups (LSmean Difference [95% CI]) was -11.73 [-15.49, -7.96] mm, proving that the test group was superior to the control group (p < 0.0001).
3) Toxicity test information
As a result of a 13-week repeated oral administration toxicity study (including TK) in Sprague-Dawley rats, histopathological changes corresponding to severe congestion and hemorrhage in the jejunum, ileum, cecum, and colon were observed in one female female that died in the high-dose group. In some other subjects, hepatolobular centriolar hypertrophy within the normal range and increases in absolute and relative weight of the liver were observed in a dose-response relationship. This was mainly due to the effect of celecoxib administration, and the lesions observed in the test were judged not to be new toxicities. The non-toxic amount of this drug (NOAEL: celecoxib/Angelica, Quince, Bangpung, Sokdan, Ohgapi, Useul, Wiryeongseon, Yukgye, Jingyo, Cheongung, Cheonma, and Safflower 25% ethanol extract (3.5→1)) is 505.4 (100/405.4) mg/kg/day for males and 252.7 (50/202.7) for females. It was judged to be mg/kg/day, and target organs were not observed in both sexes.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Period of use
24 months from date of manufacture